Base de dados : MEDLINE
Pesquisa : A11.063.438.725 [Categoria DeCS]
Referências encontradas : 10025 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1003 ir para página                         

  1 / 10025 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157617
[Au] Autor:Yoshizaki K; Murayama S; Ito H; Koga T
[Ad] Endereço:Department of Biomolecular Science and Regulation, The Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan. Electronic address: kyoshi@sanken.osaka-u.ac.jp.
[Ti] Título:The Role of Interleukin-6 in Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):23-36, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Since its discovery, improvements in treating Castleman disease and its variants have centered on interleukin-6 (IL-6). IL-6 was discovered from T-cell factors (BCDF or BSF-2), which induced B-cell maturation. Most symptoms of the plasma cell variant of Castleman disease are linked to the hyperfunction of IL-6, constitutively produced in the affected lymph nodes (1989), suggesting IL-6 is key in the pathogenesis of multicentric Castleman disease (MCD). The results of several studies have shown that most MCD symptoms and abnormal laboratory results are improved by anti-IL-6 MCD treatments, such as tocilizumab, a humanized anti-IL-6 receptor antibody, and siltuximab, an anti-IL-6 antibody.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Doença de Castleman
Interleucina-6/sangue
Linfonodos/metabolismo
Proteínas de Neoplasias/sangue
Plasmócitos/metabolismo
[Mh] Termos MeSH secundário: Doença de Castleman/sangue
Doença de Castleman/tratamento farmacológico
Seres Humanos
Interleucina-6/antagonistas & inibidores
Proteínas de Neoplasias/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Neoplasm Proteins); I031V2H011 (tocilizumab); T4H8FMA7IM (siltuximab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  2 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157614
[Au] Autor:Dispenzieri A; Kourelis T; Buadi F
[Ad] Endereço:Division of Hematology, Department of Medicine, Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: Dispenzieri.angela@mayo.edu.
[Ti] Título:POEMS Syndrome: Diagnosis and Investigative Work-up.
[So] Source:Hematol Oncol Clin North Am;32(1):119-139, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis, and Castleman disease is the first step in managing the disease. Increased blood levels of vascular endothelial growth factor are usually confirmatory. This rare disorder should not be missed, especially if the patient has a putative diagnosis of chronic inflammatory polyradiculoneuropathy, a lambda restricted monoclonal gammopathy, and thrombocytosis, and is not responding as expected to immunomodulatory therapy commonly used for chronic inflammatory polyradiculoneuropathy.
[Mh] Termos MeSH primário: Fatores Imunológicos/uso terapêutico
Síndrome POEMS
[Mh] Termos MeSH secundário: Seres Humanos
Síndrome POEMS/sangue
Síndrome POEMS/diagnóstico
Síndrome POEMS/tratamento farmacológico
Síndrome POEMS/patologia
Plasmócitos/metabolismo
Plasmócitos/patologia
Fator A de Crescimento do Endotélio Vascular/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunologic Factors); 0 (Vascular Endothelial Growth Factor A)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  3 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29255087
[Au] Autor:Bennett JC; Hood LE; Dreyer WJ; Potter M
[Ti] Título:Pillars Article: Evidence for Amino Acid Sequence Differences among Proteins Resembling the L-chain Subunits of Immunoglobulins. . 1965. 12: 81-87.
[So] Source:J Immunol;200(1):27-37, 2018 01 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alergia e Imunologia/história
Sítios de Ligação/genética
Neoplasias Hematológicas/imunologia
Cadeias Leves de Imunoglobulina/genética
Plasmócitos/fisiologia
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
História do Século XX
Cadeias Leves de Imunoglobulina/metabolismo
Camundongos
Camundongos Endogâmicos BALB C
[Pt] Tipo de publicação:CLASSICAL ARTICLE; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin Light Chains)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  4 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309109
[Au] Autor:Bozic K; Glisic B; Radic-Tasic O; Knezevic B
[Ti] Título:Case report of Mikulicz's disease: A modern concept of an old entity.
[So] Source:Vojnosanit Pregl;73(4):393-6, 2016 Apr.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Modern knowlegde defines Mikulicz´s disease as a part of immunoglobulin G4-related disease. The main feature is the presence of lymphoplasmacytic infiltrates, immunoglobulin G4 plasma cells positivity, distinctive storiform fibrosis and moderate eosinophilia. Case Report: A 59-years old male presented with a mild keratoconjuctivitis sicca and enlarged lacrimal and salivary glands during the last two years. Althought clinical presentation of the patient was typical, earlier testing did not pinpoint Mikulicz ´s disease. By typical clinical presentation, elevated serum immunoglobulin G4 level and histopathological finding of lacrimal glands tissue we diagnosed Mikulicz´s disease successfully treated with corticosteroid therapy. Conclusion: We reported the first case of IgG4-related Mikulicz´s disease in Serbia. Our report highlights IgG4-related Mikulicz` s disease as an important differential diagnosis with Sjögren`s syndrome and lymphoproliferative disease in rheumatological practice.
[Mh] Termos MeSH primário: Doença de Mikulicz/diagnóstico
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Seres Humanos
Imunoglobulina G/sangue
Imunoglobulina G/metabolismo
Imuno-Histoquímica
Aparelho Lacrimal/imunologia
Transtornos Linfoproliferativos/diagnóstico
Masculino
Meia-Idade
Doença de Mikulicz/imunologia
Plasmócitos/imunologia
Sérvia
Síndrome de Sjogren/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150118120B


  5 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468795
[Au] Autor:Porcelijn L; Huiskes E; Schipperus M; van der Holt B; de Haas M; Zwaginga JJ; Dutch HOVON 64 Study Group
[Ad] Endereço:Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
[Ti] Título:Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients.
[So] Source:Blood;129(25):3389-3391, 2017 06 22.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Plaquetas/imunologia
Púrpura Trombocitopênica Idiopática/tratamento farmacológico
Rituximab/uso terapêutico
[Mh] Termos MeSH secundário: Resistência a Medicamentos
Seres Humanos
Modelos Imunológicos
Plasmócitos/efeitos dos fármacos
Plasmócitos/imunologia
Púrpura Trombocitopênica Idiopática/sangue
Púrpura Trombocitopênica Idiopática/imunologia
Rituximab/farmacologia
Resultado do Tratamento
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Autoantibodies); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2016-11-751719


  6 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29186262
[Au] Autor:António AM; Alves JV; Coelho R; Bártolo E
[Ad] Endereço:Dermatovenereology Service, Hospital Garcia de Orta - Almada, Portugal.
[Ti] Título:Solitary ulcerated plaque on the face - an unusual presentation of cutaneous plasmacytosis?
[So] Source:An Bras Dermatol;92(3):410-412, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Cutaneous and systemic plasmacytosis is a rare disorder characterized by cutaneous polyclonal plasma cell infiltration frequently associated with polyclonal hypergammaglobulinemia and lymphadenopathy. We report a case of a 67-year-old woman with an inflammatory ulcerated plaque in the left masseter region. A skin biopsy showed dense perivascular infiltrate of mature plasma cells in the dermis without atypia and immunoglobulin light chain restriction. After physical examination and further investigation, we ruled out systemic disease. Our patient was successfully treated only with hydrocortisone cream application. Few cases of isolated benign primary cutaneous plasmacytosis have been described, particularly in children. After excluding the diagnosis of a reactive process to an infection, which is unlikely in this case, we suspected of a rare manifestation of primary cutaneous plasmacytosis in adults with distinct presentation and clinical course.
[Mh] Termos MeSH primário: Dermatoses Faciais/patologia
Plasmócitos/patologia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  7 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747342
[Au] Autor:Nguyen TTT; Graf BA; Randall TD; Baumgarth N
[Ad] Endereço:Center for Comparative Medicine, University of California Davis, Davis, CA 95616.
[Ti] Título:sIgM-FcµR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection.
[So] Source:J Immunol;199(5):1635-1646, 2017 09 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous studies with mice lacking secreted IgM (sIgM) due to a deletion of the splice region ( ) had shown sIgM involvement in normal B cell development and in support of maximal Ag-specific IgG responses. Because of the changes to B cell development, it remains unclear to which extent and how sIgM directly affects B cell responses. In this study, we aimed to explore the underlying mechanisms of sIgM-mediated IgG response regulation during influenza virus infection. Generating mice with normally developed µs-deficient B cells, we demonstrate that sIgM supports IgG responses by enhancing early Ag-specific B cell expansion, not by altering B cell development. Lack of FcµR expression on B cells, but not lack of Fcα/µR expression or complement activation, reduced antiviral IgG responses to the same extent as observed in µs mice. B cell-specific mice lacked robust clonal expansion of influenza hemagglutinin-specific B cells early after infection and developed fewer spleen and bone marrow IgG plasma cells and memory B cells, compared with controls. However, germinal center responses appeared unaffected. Provision of sIgM rescued plasma cell development from µs but not B cells, as demonstrated with mixed bone marrow chimeric mice. Taken together, the data suggest that sIgM interacts with FcµR on B cells to support early B cell activation and the development of long-lived humoral immunity.
[Mh] Termos MeSH primário: Linfócitos B/imunologia
Regiões Constantes de Imunoglobulina/metabolismo
Cadeias mu de Imunoglobulina/metabolismo
Infecções por Orthomyxoviridae/imunologia
Orthomyxoviridae/imunologia
Plasmócitos/imunologia
Receptores Fc/metabolismo
[Mh] Termos MeSH secundário: Animais
Linfócitos B/virologia
Diferenciação Celular
Feminino
Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia
Imunidade Humoral
Ativação Linfocitária
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Plasmócitos/virologia
Ligação Proteica
Receptores Fc/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Hemagglutinin Glycoproteins, Influenza Virus); 0 (Immunoglobulin Constant Regions); 0 (Immunoglobulin mu-Chains); 0 (Receptors, Fc); 0 (immunoglobulin M receptor)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180128
[Lr] Data última revisão:
180128
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700560


  8 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310344
[Au] Autor:Anan R; Akiyama M; Kaneko Y; Kikuchi J; Suzuki K; Matsubara S; Takeuchi T
[Ad] Endereço:Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine.
[Ti] Título:Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review.
[So] Source:Medicine (Baltimore);96(48):e8710, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Polymyositis (PM) is a type of autoimmune, inflammatory myopathy. IgG4-related disease (IgG4-RD) is a recently recognized disease entity characterized by elevated serum IgG4 levels and IgG4 plasma-cell infiltration of various organs. However, several reports have described cases of other diseases that present with those features, suggesting the importance of careful differential diagnosis. Herein, we report the first case of PM with elevated serum IgG4 levels and IgG4 plasma cells in the muscles, mimicking IgG4-RD.A 73-year-old woman visited our hospital because of proximal muscle weakness of both thighs. Her blood test showed high levels of serum creatinine kinase, aldolase, and IgG4. Magnetic resonance imaging of the thighs showed muscle edema. Needle electromyography showed findings typical of myositis. Histological analysis of her left quadriceps revealed infiltration of IgG4 plasma cells as well as CD8 T cells. Scattered necrotic and regenerating muscle fibers with no specific findings for IgG4-RD (storiform fibrosis and obliterative phlebitis) were typical for PM. We diagnosed her condition as PM and treated her with 40 mg/day of prednisolone that decreased levels of muscle enzymes and improved muscle weakness. CONCLUSION: Our case indicated that PM could present with high serum IgG4 levels and IgG4 plasma-cell infiltration, mimicking IgG4-RD. Although the mechanism of IgG4 elevation in such PM is unclear, our case highlights the necessity to recognize that high serum IgG4 levels and IgG4 plasma-cell infiltration in organs are not specific for IgG4-RD.
[Mh] Termos MeSH primário: Glucocorticoides/uso terapêutico
Imunoglobulina G/sangue
Plasmócitos/patologia
Polimiosite/diagnóstico
Polimiosite/tratamento farmacológico
Prednisolona/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Biomarcadores/sangue
Diagnóstico Diferencial
Eletromiografia
Feminino
Seres Humanos
Perna (Membro)
Imagem por Ressonância Magnética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Glucocorticoids); 0 (Immunoglobulin G); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008710


  9 / 10025 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310341
[Au] Autor:Fang C; Luo T; Lin L
[Ad] Endereço:Rheumatism Department.
[Ti] Título:The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: A STROBE-compliant article.
[So] Source:Medicine (Baltimore);96(48):e8675, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We investigated whether serum CXC ligand 13 protein (CXCL13) levels correlate with the circulating plasmablasts and memory B-cells alteration in systemic lupus erythematosus (SLE) patients. The diagnostic use of CXCL13 concentrations in active lupus was also analyzed.A total of 36 SLE patients and 18 healthy controls were included. Serum CXCL13 levels were examined by enzyme-linked immunosorbent assay. The frequency and absolute count of circulating plasmablasts and memory B cells were analyzed by flow cytometry. Receiver operating characteristic curves (ROC curves) were generated to analyze the utility of serum CXCL13 level and plasmablasts frequency as tools for the recognition of active SLE.Elevation of serum CXCL13 levels, higher plasmablasts frequency, and reduction of memory B-cells count were observed in SLE patients, compared with healthy controls. Interestingly, correlational analyses showed not only significantly positive association between CXCL13 levels and SLE Disease Activity Index (SLEDAI) or plasmablasts frequency, but an inverse correlation between CXCL13 concentration and memory B-cell count. ROC curves showed that serum CXCL13 level and plasmablasts frequency were practical in identifying active disease from overall SLE patients, with considerable accuracy.Serum CXCL13 levels correlate with the alteration of plasmablasts and memory B cells in SLE. CXCL13 may be used as a practical tool in judgment of active SLE.
[Mh] Termos MeSH primário: Linfócitos B/metabolismo
Quimiocina CXCL13/sangue
Lúpus Eritematoso Sistêmico/sangue
Plasmócitos/metabolismo
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Estudos de Casos e Controles
Ensaio de Imunoadsorção Enzimática
Feminino
Citometria de Fluxo
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (CXCL13 protein, human); 0 (Chemokine CXCL13)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008675


  10 / 10025 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468798
[Au] Autor:Rogers GL; Shirley JL; Zolotukhin I; Kumar SRP; Sherman A; Perrin GQ; Hoffman BE; Srivastava A; Basner-Tschakarjan E; Wallet MA; Terhorst C; Biswas M; Herzog RW
[Ad] Endereço:Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, FL.
[Ti] Título:Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8 T cells.
[So] Source:Blood;129(24):3184-3195, 2017 06 15.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Adeno-associated virus (AAV) is a replication-deficient parvovirus that is extensively used as a gene therapy vector. CD8 T-cell responses against the AAV capsid protein can, however, affect therapeutic efficacy. Little is known about the in vivo mechanism that leads to the crosspriming of CD8 T cells against the input viral capsid antigen. In this study, we report that the Toll-like receptor 9 (TLR9)-MyD88 pattern-recognition receptor pathway is uniquely capable of initiating this response. By contrast, the absence of TLR2, STING, or the addition of TLR4 agonist has no effect. Surprisingly, both conventional dendritic cells (cDCs) and plasmacytoid DCs (pDCs) are required for the crosspriming of capsid-specific CD8 T cells, whereas other antigen-presenting cells are not involved. TLR9 signaling is specifically essential in pDCs but not in cDCs, indicating that sensing of the viral genome by pDCs activates cDCs in trans to cross-present capsid antigen during CD8 T-cell activation. Cross-presentation and crosspriming depend not only on TLR9, but also on interferon type I signaling, and both mechanisms can be inhibited by administering specific molecules to prevent induction of capsid-specific CD8 T cells. Thus, these outcomes directly point to therapeutic interventions and demonstrate that innate immune blockade can eliminate unwanted immune responses in gene therapy.
[Mh] Termos MeSH primário: Linfócitos T CD8-Positivos/imunologia
Proteínas do Capsídeo/imunologia
Células Dendríticas/imunologia
Dependovirus/imunologia
Ativação Linfocitária
Plasmócitos/imunologia
[Mh] Termos MeSH secundário: Animais
Proteínas do Capsídeo/genética
Dependovirus/genética
Terapia Genética
Camundongos
Camundongos Knockout
Fator 88 de Diferenciação Mieloide/genética
Fator 88 de Diferenciação Mieloide/imunologia
Receptor Toll-Like 9/genética
Receptor Toll-Like 9/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Capsid Proteins); 0 (Myd88 protein, mouse); 0 (Myeloid Differentiation Factor 88); 0 (Tlr9 protein, mouse); 0 (Toll-Like Receptor 9)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180113
[Lr] Data última revisão:
180113
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2016-11-751040



página 1 de 1003 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde